Clinical trials: Anthracyclines
Childhood Cancer
Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity
Early microRNAs (miRs) and Cardiac Magnetic Resonance (CMR)-derived strain analysis and detection of genes contributing to Anthracycline-Induced Cardiotoxicity (AIC) sensitivity and resistance will identify pediatric cancer…
- Trial name
- NCT04036045
- Testing
- Cardiac MRI, Echocardiogram, Blood Draw
- Where
- United States
- Sponsor
- Connecticut Children's Medical Center
Advanced Breast Cancer
A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer
The combination of vinflunine and gemcitabine in advanced breast cancer in comparison to paclitaxel and gemcitabine is based on the following points: the significant antitumour activity of vinflunine in metastatic breast cancer…
- Trial name
- VICTORIA (NCT02054338)
- Testing
- Vinflunine+Gemcitabine, Paclitaxel+Gemcitabine
- Volunteers
- 1,004 people
- Sponsor
- Pierre Fabre Medicament
Patients With Cancer
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.
- Trial name
- NCT04030546
- Testing
- Ivabradine
- Where
- Lithuania
- Volunteers
- 128 people
- Sponsor
- Vilnius University
Breast Cancer
Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer
Phase III randomized clinical trial evaluating the sequencing of anthracyclines and taxanes in neoadjuvant therapy for locally advanced HER2-negative breast cancer.
- Trial name
- NEOSAMBA (NCT04540692)
- Testing
- Docetaxel or Paclitaxel, Cyclophosphamide + Doxorrubicin
- Where
- 16 sites in Brazil
- Volunteers
- 446 people
- Sponsor
- Latin American Cooperative Oncology Group
Doxorubicin Induced Cardiomyopathy, Chemotherapeutic Toxicity
Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage
The goal of this observational study is to demonstrate the ability of using non-invasive Phosphorus (31P) Magnetic Resonance Spectroscopy (MRS) to monitor changes of in-vivo markers of mitochondrial function in skeletal and…
- Conditions
- Doxorubicin Induced Cardiomyopathy, Chemotherapeutic Toxicity, Anthracyclines
- Trial name
- MUSCLE (NCT05731375)
- Testing
- 31-MRS at 7 Tesla (T)
- Where
- 4 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- UMC Utrecht
Breast Cancer
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant…
- Trial name
- BERENICE (NCT02132949)
- Testing
- 5-Fluorouracil, Cyclophosphamide, Docetaxel
- Where
- 80 sites in United States, Canada and 10 more
- Volunteers
- 401 people
- Sponsor
- Hoffmann-La Roche
Large B-cell Lymphoma
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
To learn if adding epcoritamab to the treatment combination R-miniCVP (rituximab, cyclophosphamide, vincristine, prednisone) can help to control newly diagnosed DLBCL. The safety of this combination will also be studied.
- Trial name
- NCT06045247
- Testing
- Prednisone, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
The EMBRACE Study The EMBRACE Study
Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart.
- Trial name
- EMBRACE (NCT04467411)
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
Breast Cancer, Neoplasm, Breast
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020.
- Conditions
- Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents
- Trial name
- NCT05465031
- Testing
- Sacubitril-valsartan
- Where
- 4 sites in Poland
- Volunteers
- 600 people
- Sponsor
- Silesian Centre for Heart Diseases
Breast Cancer, Left Ventricular Dysfunction
Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity
Breast cancer is the leading cause of cancer among Canadian women with nearly 26,000 new cases diagnosed each year. Fortunately, advancements in diagnostic tools and curative treatments have significantly improved overall…
- Conditions
- Breast Cancer, Left Ventricular Dysfunction, Heart Failure, Systolic
- Trial name
- CORE (NCT03089502)
- Testing
- Exercise Rehabilitation
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University Health Network, Toronto
Sarcoma
Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
This is an international (France, Austria and Germany), randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of regorafenib in patients with histologically proven metastatic and/or…
- Trial name
- REGO-SARC (NCT01900743)
- Testing
- Regorafenib
- Where
- 25 sites in Austria, France
- Volunteers
- 219 people
- Sponsor
- Centre Oscar Lambret
Breast Cancer
Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy
The purpose of this study is to determine the event-free survival (EFS) after zoledronic acid for 5 years versus no postoperative treatment in patients with "chemo-insensitive" breast cancer (ypT1-4 and/or ypN1-3) after…
- Trial name
- NATAN (NCT00512993)
- Testing
- Zoledronic acid
- Where
- 93 sites in Austria, Germany
- Volunteers
- 654 people
- Sponsor
- GBG Forschungs GmbH
Acute Promyelocytic Leukemia
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features.
- Trial name
- TUD-APOLLO-064 (NCT02688140)
- Testing
- Arsenic trioxide, Idarubicin, Cytarabine
- Where
- 8 sites in France, Germany and 3 more
- Volunteers
- 133 people
- Sponsor
- Technische Universität Dresden
Breast Cancer
Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative
The proposed study is a multicenter, open-label phase I trial, conducted in locally advanced or metastatic breast cancer HER2 negative patients and divided into 2 parts: STEP 1: a dose escalation part (n= up to 30) to evaluate…
- Trial name
- GEP14-LEECAP (NCT02754011)
- Testing
- Combination of ribociclib + capecitabine
- Where
- 2 sites in France
- Volunteers
- 18 people
- Sponsor
- UNICANCER
Breast Neoplasms
A Study of E7389 in Advanced/Metastatic Breast Cancer Patients
The purpose of this study is to determine if E7389 is a safe and effective treatment for advanced/metastatic breast cancer.
- Trial name
- NCT00097721
- Testing
- E7389
- Where
- 16 sites in United States
- Volunteers
- 104 people
- Sponsor
- Eisai Inc.
Acute Myelogenous Leukemia, AML
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
This study consists of two parts: A Phase 1 dose-escalation part that will evaluate the safety and pharmacokinetic profile of venetoclax in combination with low-dose cytarabine (LDAC), define the maximum tolerated dose (MTD), and…
- Trial name
- NCT02287233
- Testing
- Venetoclax, Cytarabine
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 94 people
- Sponsor
- AbbVie
Triple Negative Breast Cancer
De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
The traditional neoadjuvant therapy for triple negative breast cancer is based on anthracycline, paclitaxel and carboplatin. Nowadays, immunotherapy combined with chemotherapy has become a new standard treatment, which not only…
- Trial name
- NacTNBC (NCT06692725)
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Peking University People's Hospital
Breast Cancer
Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer
This is a prospective、multicenter、non-comparative interventional case series. 800 breast cancer patients who have already received chemotherapy prior to this study will be enrolled in the group, including 400 patients received…
- Trial name
- NCT02506361
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chemotherapy-induced Nausea and Vomiting
Anti-emetic Prophylaxis With or Without Dexamethasone
To evaluate the efficacy and safety of a fosaprepitant, tropisetron, and olanzapine antiemetic regimen, with or without dexamethasone, in patients receiving highly emetogenic chemotherapy with epirubicin and cyclophosphamide.
- Trial name
- NCT05242874
- Testing
- Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen, Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen
- Where
- 2 sites in China
- Volunteers
- 442 people
- Sponsor
- Henan Cancer Hospital
Breast Neoplasms
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
To compare efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast cancer who failed both a taxane and an anthracycline chemotherapy regimen or failed with a taxane and for whom further anthracycline…
- Trial name
- NCT00373113
- Testing
- Capecitabine, Sunitinib malate
- Where
- 123 sites in Argentina, Australia and 21 more
- Volunteers
- 482 people
- Sponsor
- Pfizer